North Park, November. 29, 2017 /PRNewswire/ — Aethlon Medical, Corporation. (Nasdaq: AEMD), a therapeutic technology company centered on unmet needs in global health insurance and biodefense, today announced the appointment of Charles (“Chuck”) J. Fisher, Junior., MD as Chairman of their Board of Company directors.
“We’re truly appreciative that Chuck has decided to expand his role inside our organization,” mentioned Aethlon founder & Chief executive officer Jim Joyce. “His leadership in evolving first-in-class therapies to promote won’ doubt lead to the pursuit to commercialize our Hemopurifier® along with other existence-saving therapeutic candidates.”
The Aethlon Hemopurifier® is really a first-in-class therapeutic device made to address existence-threatening infections. The U . s . States Fda (Food and drug administration) has designated the Hemopurifier® a “Breakthrough Device” associated with treating existence-threatening infections that aren’t cured with approved therapies.
“I’m pleased and honored the Board of Company directors have elected me Chairman from the Board. Let me use management, and also the Board of Company directors, to build up an item development strategy, resulting in regulatory approval and commercialization as quickly as you possibly can. By doing this, we’ll consider and evaluate both organic and proper growth possibilities. I expect to working carefully with my colleagues to attain our goals,” mentioned Dr. Fisher.
The Aethlon Board of Company directors unanimously nominated Dr. Fisher to become non-Executive Chairman and that he will stay a completely independent director under Nasdaq rules.
Dr. Fisher is really a physician researcher having a distinguished career both in academia and industry spanning over 3 decades. Being an experienced executive and entrepreneur, he brings a effective history of developing operating strategies that take products to markets, drive sales and make lucrative companies. Just before joining industry, Dr. Fisher offered as Mind from the Portion of Critical Care Medicine in the Cleveland Clinic Foundation.
Dr. Fisher’s research in sepsis, inflammation, host defense and endothelial disorder brought to his recruitment to Eli Lilly & Co., where he brought the Xigris (activated Protein C) Global Product Team and effectively registered the very first drug approved to treat sepsis. Subsequently, he was employed to Abbott Laboratories as Divisional V . P . for Global Pharmaceutical Development and research (GPRD), where, among other accomplishments, he led the registration of Humira (the very first fully humanized anti-TNF mab).
He was Chief Medical Officer and Executive V . P . of Cardiome Pharma Corp. where he brought they that invented, developed, registered vernakalant, a singular, first at school, multi-ion funnel drug for atrial fibrillation (Brinavess). He presently can serve as Executive Chairman of CytoPherx, Corporation., a clinical device company with novel IP centered on modulating acute and chronic inflammation.
Additionally, Fisher is really a multi-tour combat veteran, with extensive leadership experience of special operations. He’s offered as part of the Defense Science Research Council as well as on DARPA panels, including one centered on universal host defense.
About Aethlon Medical, Corporation.
Aethlon Medical is centered on addressing unmet needs in global health insurance and biodefense. The Aethlon Hemopurifier® is really a first-in-class therapeutic device made to address existence-threatening infections. The U . s . States Fda (Food and drug administration) has designated the Hemopurifier® a “Breakthrough Device” associated with treating existence-threatening infections that aren’t cured with approved therapies.
Together with leading government and non-government research institutes, Aethlon has validated ale the Hemopurifier® to capture an extensive-spectrum of pandemic influenza infections, bug-borne infections and deadly hemorrhagic infections. According to its use to deal with Ebola virus, the Hemopurifier® was named a “Top 25 Invention” and among the “Eleven Most Outstanding Advances in Healthcare,” by TIME Magazine.
Aethlon can also be investigating the possibility therapeutic utilisation of the Hemopurifier® to lessen the existence of tumor-derived exosomes, which lead to immune-suppression and also the spread of metastasis in cancer patients. Furthermore, Aethlon may be the majority who owns Exosome Sciences, Corporation. (ESI), which is centered on the invention of exosomal biomarkers to identify and monitor cancer and nerve disorders, including Alzheimer’s (AD) and Chronic Traumatic Encephalopathy (CTE). More information are available online at world wide web.AethlonMedical.com and world wide web.ExosomeSciences.com. You may also interact with us on Twitter, LinkedIn, Google and facebook+.
Forward Searching Statements
This pr release contains forward-searching statements inside the concept of Section 27A from the Securities Act of 1933 and Section 21E from the Securities Exchange Act of 1934 which involve risks and uncertainties. Statements that contains words for example “may,” “believe,” “anticipate,” “expect,” “intend,” “plan,” “project,” “will,” “projections,” “estimate,” or similar expressions constitute forward-searching statements. Forward-searching statement includes statements concerning the public offering and also the satisfaction of closing conditions concerning the public offering, in addition to general economic and market factors. Such forward-searching statements are susceptible to significant risks and uncertainties and actual results may vary materially in the results anticipated within the forward-searching statements. Factors that could lead to such variations include, without limitation, the business’s capability to maintain its listing around the Nasdaq Capital Market, or other national securities exchange, that the organization or its subsidiary won’t be able to commercialize its products, the Food and drug administration won’t approve the initiation or continuation from the Company’s clinical programs or provide market clearance from the Company’s products, the business’s capability to raise investment capital if needed, the business’s capability to complete the introduction of its planned products, the business’s capability to manufacture its products either internally or through outdoors companies, the outcome of presidency rules, patent protection around the Company’s proprietary technology, ale the organization to satisfy the milestones considered in the hire DARPA, defective products exposure, uncertainty of market acceptance, competition, technological change, along with other risks. This listing of risks and uncertainties is illustrative, however is not exhaustive. Additional circumstances that may cause leads to differ materially from individuals anticipated in forward-searching statements are available underneath the caption “RisksInch within the Company’s Annual Set of Form 10-K for that year ended March 31, 2017, as well as in the business’s other filings using the Registration. Except as might be needed legally, the organization are not committed, nor will it undertake any duty, to update these details to mirror future occasions or conditions.
Chief Financial Officer
Aethlon Medical, Corporation.
858-459-7800 extension 3300
516 222 2560
View original content:http://world wide web.prnewswire.com/news-releases/aethlon-medical-names-dr-charles-j-fisher-chairman-of-the-board-300563365.html
SOURCE Aethlon Medical, Corporation.
http://world wide web.aethlonmedical.com